ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura

New England Journal of Medicine

Volumn 368, Issue 1, 2013, Pages 90-92

  Shortt, Jake ^a   Oh, Danielle H ^a   Opat, Stephen S ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIBODY TITER; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE REPORT; CONTINUOUS INFUSION; DETERIORATION; DISEASE ASSOCIATION; ENDOTRACHEAL INTUBATION; ENZYME ACTIVITY; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MELENA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84871810864     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1213206     Document Type: Letter

References (4)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060-9. [Erratum, Blood 2011;117:5551.]
2. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11.
3. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011;121:593-603.
4. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009; 41:105-7.